Skip to content
Screener

Exagen Inc. XGN Q2 2025 earnings

Reported July 29, 2025 · Before market open

Revenue$17.2MBeat by $300.8K
EPS-$0.18In line
Revenue estimate$16.9M
EPS estimate-$0.18

Next report

Nov 3, 2026 (In 3 weeks)
Revenue estimate$18.3M
EPS estimate-$0.19

Financials

Q2 2025

Income statement

See full
Revenue$17.2M+14.2%
Gross profit$10.4M+14.8%
Operating income-$2.6M-1.7%
Net income-$4.4M-49.7%
EPS (diluted)-$0.21-31.2%

Balance sheet

See full
Cash & equivalents$30.2M+22.5%
Total debt$25.2M+5.6%
Total equity$21.0M+19.6%
Total assets$58.8M+19.2%

Cash flow

See full
Operating cash flow-$2.9M-18.9%
CapEx$209.0K+53.7%
Free cash flow-$3.1M-20.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$154.34M+373%
Enterprise value$149.31M+369%
P/S2.6×+2.0×

Profitability

See full
Gross margin59.4%+0.3pp
Operating margin-23.9%-3.0pp
Net margin-28.8%-1.5pp
FCF margin-27.5%—

Returns & leverage

See full
Return on equity-87.9%+30.4pp
Debt / equity1.2×-0.2×
Current ratio5×+0.6×

Segments

By segment

See full
Reportable Segment$17.2M+14.2%

FAQ

When did Exagen Inc. report Q2 2025 earnings?
Exagen Inc. (XGN) reported Q2 2025 earnings on July 29, 2025 before market open.
What were Exagen Inc.'s Q2 2025 revenue and EPS?
Exagen Inc. reported revenue of $17.2M and eps of $-0.18 for Q2 2025.
Did Exagen Inc. beat estimates in Q2 2025?
Revenue beat the consensus estimate of $16.9M by $300.8K. EPS beat the consensus estimate of $-0.18 by $0.00.
How did Exagen Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 14.2% from $15.1M a year earlier and eps declined 12.5% from $-0.16.
Where can I find Exagen Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001274737-25-000061) and the 10-Q periodic report (0001274737-25-000063) directly on SEC EDGAR. The filing index links above go to sec.gov.